Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
[waldenström macroglobulinemia]
Recent
clinical
data
suggest
remarkable
activity
of
ibrutinib
,
the
first
-
in
-class
covalent
inhibitor
of
Bruton
's
tyrosine
kinase
(
BTK
)
,
in
chronic
lymphocytic
leukemia
(
CLL
)
,
as
well
as
excellent
activity
in
other
B
cell
malignancies
,
including
in
particular
mantle
cell
lymphoma
and
Waldenstrom
macroglobulinemia
.
This
review
evaluates
the
data
from
ongoing
clinical
and
correlative
studies
of
ibrutinib
in
B
cell
malignancies
with
a
particular
focus
on
CLL
,
and
considers
these
data
in
the
context
of
other
B
cell
receptor
pathway
inhibitors
.
